Amundi Repligen Corp Transaction History

Amundi

$253 Billion
Q2 2024

A detailed history of Amundi transactions in Repligen Corp stock. As of the latest transaction made, Amundi holds 202,095 shares of RGEN stock, worth $29.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

202,095

Previous 235,245 14.09%

Holding current value

$29.5 Million

Previous $43.3 Million 41.12%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $3.98 Million - $6.06 Million	-33,150 Reduced 14.09%	202,095 $25.5 Million
Q1 2024 May 15, 2024	SELL	$170.78 - $208.42 $22.5 Million - $27.5 Million	-131,907 Reduced 35.93%	235,245 $43.3 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $41,900 - $68,023	367 Added 0.1%	367,152 $66 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $6.08 Million - $7.74 Million	43,840 Added 13.58%	366,785 $58.3 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $15.5 Million - $20.1 Million	111,625 Added 52.82%	322,945 $45.7 Million
Q1 2023 May 15, 2023	BUY	$154.26 - $198.1 $3.22 Million - $4.13 Million	20,848 Added 10.95%	211,320 $35.6 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $21.7 Million - $29.4 Million	133,419 Added 233.85%	190,472 $32.2 Million
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $9.15 Million - $14.6 Million	57,053 New	57,053 $12.6 Million
Q2 2022 Aug 15, 2022	SELL	$140.68 - $188.02 $380,961 - $509,158	-2,708 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$161.19 - $257.96 $97,197 - $155,549	-603 Reduced 18.21%	2,708 $490,000
Q3 2021 Nov 15, 2021	BUY	$194.77 - $324.21 $508,544 - $846,512	2,611 Added 373.0%	3,311 $957,000
Q2 2021 Aug 16, 2021	BUY	$165.87 - $220.95 $116,109 - $154,665	700 New	700 $140,000

Others Institutions Holding RGEN

# of Institutions

495

Shares Held

53.9M

Call Options Held

420K

Put Options Held

85.3K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.1B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account